Medtronic plc (MDT) — Fiscal Year 2026 10-K Filing Description

Medtronic plc, headquartered in Galway, Ireland, is the world's leading healthcare technology company, founded in 1949 and serving healthcare systems, physicians, and patients across more than 150 countries. The company's mission — "to alleviate pain, restore health, and extend life" — drives a business strategy built on accelerating innovation-driven growth, delivering superior clinical outcomes, and transforming data, artificial intelligence, and automation into actionable care. This Form 10-K filing for fiscal year ended April 24, 2026 presents a company navigating strong revenue momentum, strategic portfolio transformation through the separation of its Diabetes business and targeted acquisitions, while contending with an increasingly complex global regulatory environment, cybersecurity threats, litigation exposure, and macroeconomic headwinds that collectively shape the risk landscape for one of the world's largest medical device manufacturers.

I. Business Overview and Strategic Initiatives

Medtronic's operations are organized into three reportable segments: the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio, with Diabetes reported as a separate business segment pending its planned full separation [Item 1 - Business, ¶1]. The Cardiovascular Portfolio — comprising Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular divisions — generated $14.0 billion in net sales in fiscal year 2026, an increase of 12 percent year over year fueled by the Micra leadless pacemaker and the Aurora EV-ICD system. The Neuroscience Portfolio, encompassing Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation, posted $10.3 billion in net sales (+4 percent), driven by the AiBLE spine ecosystem and the Inceptiv closed-loop spinal cord stimulator. The Medical Surgical Portfolio — Surgical & Endoscopy and Acute Care & Monitoring — delivered $8.8 billion in net sales (+5 percent), underpinned by LigaSure vessel-sealing technology and continued commercialization of the Hugo robotic-assisted surgery system [Item 7 - MD&A, ¶13, ¶18, ¶24].

In a landmark strategic shift, Medtronic announced in May 2025 its intent to separate the Diabetes Business, and on March 9, 2026, MiniMed Group, Inc. completed an initial public offering, with Medtronic retaining approximately 90.03 percent ownership. The company anticipates completing the full separation within the next fiscal year, a move designed to unlock shareholder value and sharpen strategic focus across the remaining portfolios [Item 1 - Business, ¶3]. Concurrently, Medtronic has been actively reshaping its portfolio through targeted bolt-on acquisitions. In April 2026, the company acquired CathWorks Ltd. for $525 million, adding technology to transform coronary artery disease diagnosis and treatment within the Coronary & Peripheral Vascular division. In June 2026, the company closed on the acquisition of Scientia Vascular for approximately $550 million upfront, adding differentiated access products for complex neurovascular conditions. In May 2026, Medtronic announced its intent to acquire SPR Therapeutics for approximately $650 million, enhancing the Neuromodulation division with temporary peripheral nerve stimulation technology for chronic pain management [Item 7 - MD&A, ¶55, ¶57].

Medtronic competes across therapeutic and diagnostic medical markets in more than 150 countries, facing a diverse mix of large multi-line manufacturers, specialized medical technology firms, and pharmaceutical alternatives such as GLP-1 therapies. The competitive landscape is shaped by rapid technological change, product quality events, and ongoing government and private-sector cost-containment initiatives including price regulation, volume-based procurement tenders, and value-based reimbursement models that continue to increase price sensitivity among healthcare customers [Item 1 - Business, ¶34]. Looking ahead, Medtronic's long-term strategy centers on maintaining technological leadership through robust research and development investment. The company's R&D activities focus on improving existing products, expanding clinical indications, and developing new therapies and procedures, supported by selective external collaborations, investments, licensing arrangements, and acquisitions. Key pipeline priorities include expanding indications for the Hugo RAS system into general surgery and gynecology in the U.S., advancing the Affera pulsed field ablation platform, developing next-generation spine enabling technologies, and commercializing the Altaviva implantable tibial neuromodulation system [Item 1 - Business, ¶31].

II. Financial Performance and Operational Results (MD&A)

Medtronic reported total net sales of $36.4 billion in fiscal year 2026, an 8% increase over the prior year, demonstrating broad-based growth across all segments. The Cardiovascular segment generated $14.0 billion, up 12%, led by Cardiac Rhythm & Heart Failure growth of 17% driven by the Micra leadless pacemaker and Aurora EV-ICD system. Neuroscience contributed $10.3 billion (+4%), Medical Surgical delivered $8.8 billion (+5%), and Diabetes posted $3.1 billion (+13%). International revenue grew 12% to $18.3 billion, outpacing U.S. growth of 5%, benefiting from favorable foreign currency fluctuations and strong market penetration in key regions [Item 7 - MD&A, Table 6].

On the cost side, cost of products sold increased to $12.7 billion and rose as a percentage of net sales, primarily due to $185 million in incremental tariffs and duties on imported goods — reflecting the impact of heightened trade tensions between the U.S. and key trading partners — and $84 million in asset write-offs included in cost of products sold, partially offset by favorable currency impacts [Item 7 - MD&A, ¶30]. Research and development expense increased to $2.9 billion from $2.7 billion, reflecting the company's continued commitment to innovation across its therapeutic portfolios. Selling, general, and administrative expense grew to $11.8 billion from $10.8 billion, driven by higher selling costs in line with revenue growth, new product launch commercialization expenses, and increased costs supporting the impending separation of the Diabetes Business [Item 7 - MD&A, ¶32].

On a GAAP basis, Medtronic reported net income of $4.8 billion and diluted EPS of $3.73, while non-GAAP net income reached $7.1 billion with diluted EPS of $5.53. The effective tax rate increased significantly to 21.2% from 16.6%, driven by certain tax adjustments and the impact of Pillar Two global minimum tax provisions, which represent a growing compliance burden for multinational enterprises [Item 7 - MD&A, Table 3]. Net cash provided by operating activities reached $7.3 billion, a $286 million increase from the prior year, driven by higher customer collections on growing sales [Item 7 - MD&A, ¶42]. Free cash flow totaled $5.4 billion, up from $5.2 billion in the prior year, providing ample capacity for strategic investments, debt reduction, and shareholder returns [Item 7 - MD&A, Table 5].

III. Financial Statements and Balance Sheet Health

Medtronic maintains a strong and well-capitalized balance sheet as of April 24, 2026. The company held $1.9 billion in cash and cash equivalents alongside $7.3 billion in current investments, providing substantial short-term liquidity. Total debt stood at $28.0 billion, down modestly from $28.5 billion in the prior year due to net repayments of Euro-denominated senior notes. Operating cash flow reached $7.3 billion for fiscal year 2026, yielding $5.4 billion in free cash flow after capital expenditures of $1.9 billion. Medtronic also maintains a $3.5 billion syndicated credit facility expiring in December 2030 and a $3.5 billion commercial paper program, both fully undrawn, providing substantial additional liquidity headroom [Item 7 - MD&A, ¶44-46]. The company repurchased 10 million shares at an average price of $93.25 during the fiscal year, reflecting management's confidence in the company's intrinsic value and long-term prospects [Item 7 - MD&A, ¶45].

During fiscal year 2026, the company recorded $121 million in accelerated amortization on certain intangible assets within the Cardiovascular segment, and $84 million in asset write-offs included in cost of products sold [Item 7 - MD&A, ¶30]. Annual goodwill impairment testing conducted in the third quarter revealed that the Medical Surgical reporting unit, which carries $20.0 billion in allocated goodwill, had an estimated fair value exceeding its carrying value by only approximately 12%, making it the most at-risk reporting unit. All other reporting units' fair values materially exceeded their carrying amounts. Management noted that while MiniMed's stock price declined subsequent to its IPO, the estimated fair value of MiniMed still exceeded its carrying value as of the filing date, though the risk of future impairment charges remains if valuations deteriorate further [Item 7 - MD&A, ¶66-67].

Medtronic faces significant market risk exposures from its global operations. Currency exchange rate risk is actively managed through a substantial hedging program, with $20.3 billion notional in currency derivative instruments outstanding at year-end carrying a $135 million net unrealized gain. A sensitivity analysis indicates that a hypothetical 10% uniform strengthening or weakening of the U.S. dollar against all currencies would impact the fair value of these contracts by approximately $1.7 billion, though these gains and losses would generally be offset by corresponding movements in the underlying exposures [Item 7A - Market Risk, ¶1]. The net impact of currency remeasurement and hedging programs resulted in a net loss of $238 million in fiscal year 2026, a significant increase from the $3 million net loss in the prior year, underscoring the heightened currency volatility affecting global businesses [Item 7 - MD&A, ¶34]. The company's debt portfolio is predominantly fixed-rate and denominated in U.S. dollars and Euros, limiting interest rate exposure, and Medtronic's critical accounting estimates include revenue recognition, litigation contingencies, income tax reserves, and valuation of intangible assets and goodwill, all of which require significant management judgment and are subject to estimation uncertainty [Item 7A - Market Risk, ¶2].

IV. Risk Factors and External Challenges

Medtronic's business faces a complex array of risk factors spanning regulatory, competitive, legal, and macroeconomic dimensions that investors must carefully consider.

Regulatory, Reimbursement, and Competitive Pressures. Medtronic operates in a highly competitive medical device market across more than 150 countries, characterized by rapid technological change. The company faces competition not only from traditional device manufacturers but also from alternative medical therapies such as GLP-1 pharmaceutical products, and must navigate shifts in standards of care, physician preferences, and the growth of ambulatory surgery centers [Item 1A - Risk Factors, ¶2]. Government-driven pricing and procurement mechanisms, including volume-based procurement initiatives in China, may require significant price concessions and constrain Medtronic's ability to compete on factors other than price, with some markets imposing retrospective payment adjustments or clawback arrangements [Item 1A - Risk Factors, ¶5]. On the regulatory front, Medtronic's devices are subject to extensive oversight by the U.S. FDA, the U.S. Department of Justice, and numerous other authorities. In the European Union, the Medical Device Regulation (EU MDR) imposes significant additional pre-market and post-market requirements, with compliance deadlines extending to the end of 2027 for high-risk devices and 2028 for medium- and low-risk devices [Item 1A - Risk Factors, ¶21]. Reimbursement risk is substantial, as Medtronic's products are purchased by hospitals and physicians that bill third-party payors including Medicare, Medicaid, and private insurers. Coverage decisions, utilization management programs such as prior authorization, and variability in payment policies may affect physician adoption, hospital purchasing decisions, and patient access [Item 1A - Risk Factors, ¶30].

Macroeconomic and Geopolitical Risks. Medtronic's global operations expose it to significant supply chain and geopolitical risks. The company relies on complex global supply chains, and certain components and raw materials are obtained from sole suppliers. Global shortages of semiconductors and resins have previously caused disruptions, and evolving regulatory requirements concerning chemicals such as ethylene oxides and PFAS may impose additional supply constraints [Item 1A - Risk Factors, ¶9]. Trade tensions between the U.S. and China, as well as increased tariffs with Mexico, Canada, and the EU, are imposing significant costs — the $185 million in incremental tariffs recognized in fiscal year 2026 attest to the materiality of these exposures. China represents approximately six percent of Medtronic's total revenue, and technology export restrictions targeting software, digital health, and AI-enabled tools could restrict the company's operations in key markets [Item 1A - Risk Factors, ¶63]. Currency exchange rate fluctuations further impact reported revenues, expenses, and cash flows, and the company cannot predict the degree to which it will be able to manage these impacts [Item 1A - Risk Factors, ¶66].

Medtronic reports no unresolved staff comments from the SEC, indicating no outstanding regulatory scrutiny of this nature that would require additional disclosure [Item 1B - Staff Comments, ¶1].

V. Cybersecurity and Information Security

Medtronic has established a comprehensive cybersecurity risk management program designed to identify, assess, and mitigate cybersecurity risks relevant to its business, a matter of particular importance given the smart technology embedded within the company's medical devices and the sensitive patient data its products collect. The program is structured around the National Institute of Standards and Technology (NIST) Cyber Security Framework 2.0 and includes dedicated cybersecurity professionals who analyze threats, define policies, implement protections, and monitor and respond to incidents. Key elements include regulatory-based risk assessments, a formal incident response plan that classifies incidents by severity and impact, annual information security training for all employees including phishing awareness, and close collaboration between cybersecurity teams and application development and infrastructure teams to embed security into technology foundations. The company also engages third-party service providers for penetration testing, vulnerability testing, and assessments of the overall cybersecurity program, and maintains a third-party risk assessment process for service providers, suppliers, and vendors [Item 1C - Cybersecurity, ¶1]. Given the smart technology within Medtronic's medical devices, product security includes design protocols supported by quality systems testing and scanning tools to detect vulnerabilities.

Governance of the cybersecurity program is led by the Chief Information Security Officer (CISO), who brings over 30 years of experience assisting public and private companies across various industries, including executive-level leadership roles in Fortune 500 organizations. The CISO reports to the Chief Information Officer (CIO), who leads the Global Information Technology organization and works closely with the Executive Committee to guide strategic direction [Item 1C - Cybersecurity, ¶4]. At the Board level, cybersecurity oversight is shared between the Quality Committee, which oversees cybersecurity strategies, systems, and controls to ensure product reliability and prevent unauthorized access, and the Audit Committee, which discusses policies related to the reliability and security of information technology systems. The Audit Committee receives regular updates on the cybersecurity risk management program from the CISO and CIO, with escalation procedures for certain cybersecurity events [Item 1C - Cybersecurity, ¶5]. Cybersecurity risks are also integrated into the company's Enterprise Risk Management (ERM) program, which provides a framework for identifying, assessing, and mitigating risks that could materially impact the business [Item 1C - Cybersecurity, ¶2].

In a notable incident, Medtronic disclosed that on April 24, 2026, an unauthorized third party accessed data in certain of its information technology systems. Upon identifying the unauthorized access, the company promptly contained the incident, activated its incident response protocols, and engaged leading external cybersecurity experts to support investigation and remediation efforts [Item 1C - Cybersecurity, ¶2]. Based on the investigation to date, Medtronic has not identified any impact to its products, patient safety, connections to customers, manufacturing and distribution operations, financial reporting systems, or ability to meet patient needs. The company does not currently expect the incident to have a material impact on its business or financial results, though the assessment remains ongoing, and notifications to affected individuals are expected to begin as early as the first quarter of fiscal year 2027 [Item 1C - Cybersecurity, ¶3]. To date, Medtronic is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the company's business or operations.

The company's risk factor disclosures underscore the criticality of its cybersecurity posture. Medtronic acknowledges increasing dependence on sophisticated information technology systems to process, transmit, and store sensitive data, including patient information collected by its products. Ransomware remains a significant concern, and the company's ransomware readiness program requires ongoing investment, though it cannot guarantee immunity from incidents [Item 1A - Risk Factors, ¶45]. The company also recognizes risks from third-party vendors that supply or support its information technology systems, as cybersecurity incidents affecting these partners could adversely impact operations even if Medtronic's own systems are not directly compromised [Item 1A - Risk Factors, ¶46]. A breach, cyber-attack, or other disruption to these systems or data could materially and adversely affect the company's business, results of operations, financial condition, cash flows, reputation, or competitive position [Item 1A - Risk Factors, ¶44].

VI. Legal Proceedings and Compliance Matters

Medtronic and its affiliates are involved in various legal actions, including product liability, intellectual property, commercial disputes, environmental proceedings, tax disputes, and governmental investigations. The Company records liabilities for loss contingencies when a loss is probable and reasonably estimable and discloses reasonably possible losses where estimable [Item 8 - Financial Statements, ¶127]. During fiscal year 2026, the Company recognized $113 million in certain litigation charges, net, and carried approximately $0.2 billion in accrued litigation on its balance sheet as of April 24, 2026 [Item 8 - Financial Statements, ¶130].

In a significant favorable development, the U.S. Court of Appeals for the Federal Circuit ruled in July 2025 that Medtronic did not infringe the Colibri Heart Valve patent, vacating a prior $106 million jury verdict against the Company and eliminating any potential liability in that matter [Item 8 - Financial Statements, ¶132]. However, Medtronic faces substantial product liability exposure from hernia mesh litigation. As of June 2026, approximately 10,350 individual plaintiffs have filed lawsuits against the Company's subsidiaries alleging personal injury from hernia mesh products, with cases coordinated in Massachusetts state court (~7,450 plaintiffs), Minnesota state court (~500 plaintiffs), and a federal Multidistrict Litigation (~2,400 actions). Notably, the pending lawsuits relate almost entirely to products that have not been subject to recalls or adverse regulatory action [Item 8 - Financial Statements, ¶133].

The most significant new litigation development involves antitrust litigation brought by Applied Medical Resources Corporation, which in February 2026 resulted in a jury verdict awarding $382 million in damages, which under federal antitrust law is automatically trebled to approximately $1.15 billion, relating to sales of advanced bipolar devices. Medtronic believes the verdict is inconsistent with the law and evidence and has filed post-trial motions, with plans to appeal if necessary. No liability has been recorded because a loss is not currently probable, though investors should closely monitor developments [Item 8 - Financial Statements, ¶136].

On the government investigation front, the Company has regular interactions with the U.S. Securities and Exchange Commission, the U.S. Department of Justice, and authorities in other countries regarding activities in different global markets, including anti-corruption compliance. Medtronic has not recorded an expense for these matters as any potential loss is not currently probable or estimable [Item 8 - Financial Statements, ¶139]. The long-running dispute with the IRS regarding the allocation of income between Medtronic, Inc. and its Puerto Rico manufacturing subsidiary remains unresolved for fiscal years 2005–2006 as well as 2007–2016. In September 2025, the Appellate Court remanded the case back to the Tax Court, and the parties have requested a stay to discuss potential resolution. The IRS also issued a preliminary audit report for fiscal years 2017–2019 that left unresolved the Puerto Rico income allocation, intercompany debt interest rates, and foreign tax credit calculations. The Company maintains total reserves of $2.951 billion for uncertain tax positions as of April 24, 2026, a substantial contingency that reflects the magnitude of this dispute [Item 8 - Financial Statements, ¶143]. Additionally, the Company's affiliates are defendants in the Mallinckrodt bankruptcy litigation, where a trust alleges that Covidien's 2013 spin-off of its pharmaceuticals business was intended to avoid opioid-related liabilities. This case is proceeding to discovery on intentional fraudulent transfer claims, and no liability has been recorded [Item 8 - Financial Statements, ¶142].

Regarding internal controls, the independent registered public accounting firm's audit opinion confirms that Medtronic maintained effective internal control over financial reporting as of April 24, 2026, based on criteria established in the COSO (2013) framework, with Item 9 of the 10-K reporting no changes in or disagreements with accountants on accounting and financial disclosure.

Conclusion

Medtronic plc enters fiscal year 2027 from a position of operational and financial strength, having delivered $36.4 billion in revenue with 8% growth across all four business segments while generating $5.4 billion in free cash flow. The company is in the midst of a significant strategic transformation, pursuing the full separation of its Diabetes business while simultaneously deploying capital into targeted acquisitions — CathWorks, Scientia Vascular, and SPR Therapeutics — that strengthen core cardiovascular, neurovascular, and neuromodulation franchises. However, investors must weigh this positive momentum against a backdrop of substantial litigation exposure — most notably the $1.15 billion trebled antitrust verdict that the company is vigorously contesting — along with a $2.951 billion IRS tax reserve, increasing tariff costs, intensifying competitive pressure from GLP-1 therapies and alternative treatment modalities, and the ongoing challenge of navigating an increasingly complex global regulatory environment. The April 2026 cybersecurity incident serves as a reminder of the operational risks inherent in a company whose products are increasingly connected and data-driven. Medtronic's ability to execute its portfolio transformation, defend against litigation, manage macroeconomic headwinds, and continue innovating across its technology pipeline will determine whether the company can sustain its leadership position in the global medical technology industry.